Results 161 to 170 of about 92,020 (286)

CD38 Negative [PDF]

, 2020
openaire   +1 more source

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM

European Journal of Haematology, Volume 116, Issue 6, Page 697-708, June 2026.
The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Changes of B cell subsets characterized with CD27 and CD38 phenotypes in peripheral blood of myasthenia gravis patients

Chinese Journal of Contemporary Neurology and Neurosurgery, 2019
Objective To investigate the clinical significance of peripheral B-cell subsets with CD27 and CD38 phenotypes in myasthenia gravis (MG) patients. Methods Peripheral blood samples of 43 MG patients and 38 health controls (HC) from January 2016 to Decamber
Jian⁃hua JIANG, Qun XUE, Cui⁃ping LIU, Qi FANG, Li⁃qiang YU, Lu⁃lu ZHANG, Jue⁃an JIANG   +6 more
doaj  

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real‐World Evidence in a Rapidly Evolving Therapeutic Landscape

European Journal of Haematology, Volume 116, Issue 6, Page 928-936, June 2026.
ABSTRACT Modern therapies have clearly marked the history of multiple myeloma (MM), leading to undisputed advantages in terms of sustained responses and prolonged survival, while progressively improving patients' quality of life. Nonetheless, disease recurrence and resistance to available therapies underscore the importance of identifying additional ...
K. Mancuso, S. Masci, M. Talarico, A. Vitale, S. Barbato, V. Solli, M. Puppi, I. Rizzello, L. Pantani, P. Tacchetti, M. Iezza, R. Restuccia, I. Sacchetti, E. Manzato, S. Ghibellini, S. Armuzzi, B. Taurisano, M. Cavo, E. Zamagni   +18 more
wiley   +1 more source

CD38 overexpression drives glioblastoma progression via L1CAM/ICAM1/JAK-STAT-Driven tumor microenvironment rewiring. [PDF]

Transl Oncol
Norouzi S, Aulakh S.
europepmc   +1 more source

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma

Leukemia, 2023
Djamila Chemlal, Emmanuel Varlet, Amelie Machura, Sara Ovejero, Guilhem Requirand, Nicolas Robert, Guillaume Cartron, Elina Alaterre, Caroline Bret, Laure Vincent, Charles Herbaux, Giacomo Cavalli, Angélique Bruyer, Hugues De Boussac, Jerome Moreaux   +14 more
openaire   +2 more sources

Latent Neoehrlichia mikurensis Infections May Be Reactivated in Patients With B‐Cell Lymphomas Treated With Rituximab

Immunology, Volume 178, Issue 2, Page 307-317, June 2026.
Eight percent of this cohort of patients had a latent Neoehrlichia mikurensis infection. It was only the latently infected patients who had N. mikurensis‐specific T cells, not the matched B‐cell lymphoma patients without the infection. The T‐cell responses of latently infected patients included perforin‐expressing Th1 and CD8+ T cells that upregulated ...
Linda Wass, Catharina Lewerin, Daniel Jaén‐Luchoro, Christine Lingblom, Christine Wennerås   +4 more
wiley   +1 more source

Type III CD38 is present in the membrane of neurosecretory vesicles and has a cytosol-facing catalytic domain in primate oxytocin neurons. [PDF]

J Neuroendocrinol
Miyamoto T, Matsushima A, Otubo A, Song C, Murata K, Oti T, Sakamoto H.   +6 more
europepmc   +1 more source

CD38 wt Allele [PDF]

, 2020
openaire   +1 more source

Immune endotypes in tuberculosis: Keys to decoding disease complexity

Journal of Internal Medicine, Volume 299, Issue 6, Page 670-693, June 2026.
Abstract Tuberculosis (TB) remains a major global health challenge, with multi‐drug antibiotic regimens as the current standard of care. While effective at killing Mycobacterium tuberculosis, these treatments do not resolve persistent inflammation, prevent lung damage, or reverse immune dysregulation that contribute to poor outcomes and disease ...
Shamila D. Alipoor, Julia Guthrie, Lina Davies Forsman, Andrew R. Di Nardo, Susanna Brighenti   +4 more
wiley   +1 more source